pI: 8.2637 |
Length (AA): 466 |
MW (Da): 51544 |
Paralog Number:
7
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 11
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | Procyclic. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_133631)
Species | Accession | Gene Product |
---|---|---|
Cryptosporidium hominis | Chro.20039 | CG31911-PA |
Cryptosporidium parvum | cgd2_310 | nucleoside transporter, 10 transmembrane domain domain, nucleoside binding domain |
Entamoeba histolytica | EHI_110730 | nucleoside transporter, putative |
Leishmania braziliensis | LbrM.35.2150 | nucleoside transporter 1, putative |
Leishmania donovani | LdBPK_362040.1 | inosine-guanosine transporter |
Leishmania infantum | LinJ.36.2040 | inosine-guanosine transporter |
Leishmania major | LmjF.36.1940 | inosine-guanosine transporter;with=GeneDB:LinJ36_V3.2040 |
Leishmania mexicana | LmxM.36.1940 | nucleoside transporter 1, putative |
Trypanosoma brucei gambiense | Tbg.972.2.4320 | adenosine transporter 2, putative |
Trypanosoma brucei gambiense | Tbg.972.2.4300 | adenosine transporter 2 |
Trypanosoma brucei gambiense | Tbg972.9.4060 | adenosine transporter, putative |
Trypanosoma brucei gambiense | Tbg.972.2.4350 | adenosine transporter 2, putative |
Trypanosoma brucei | Tb927.9.7470 | purine nucleoside transporter |
Trypanosoma brucei | Tb927.6.220 | purine nucleoside transporter |
Trypanosoma brucei | Tb927.2.6150 | adenosine transporter 2 |
Trypanosoma brucei | Tb927.2.6200 | adenosine transporter 2, putative |
Trypanosoma brucei | Tb927.2.6220 | adenosine transporter 2, putative |
Trypanosoma brucei | Tb927.2.6240 | adenosine transporter 2 |
Trypanosoma brucei | Tb927.2.6280 | adenosine transporter 2, putative |
Trypanosoma brucei | Tb927.2.6320 | adenosine transporter 2, putative |
Trypanosoma congolense | TcIL3000_9_2500 | purine nucleoside transporter, putative |
Trypanosoma cruzi | TcCLB.508645.70 | nucleoside transporter 1, putative |
Trypanosoma cruzi | TcCLB.508645.40 | nucleoside transporter 1, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.2.6150 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.6150 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.6150 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.2.6150 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.2.6200 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.6200 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.6200 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.2.6200 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.6.220 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.220 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.220 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.220 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.2.6240 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.6240 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.6240 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.2.6240 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.2.6220 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.6220 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.6220 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.2.6220 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb09.160.5480 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.5480 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.5480 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.160.5480 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Trypanosoma brucei | adenosine transporter 2 | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Trypanosoma brucei | adenosine transporter, putative | 463 aa | 57.3% | 466 aa | Compounds | References |